0001639643-19-000004.txt : 20190924 0001639643-19-000004.hdr.sgml : 20190924 20190924160847 ACCESSION NUMBER: 0001639643-19-000004 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06c FILED AS OF DATE: 20190924 DATE AS OF CHANGE: 20190924 EFFECTIVENESS DATE: 20190924 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Kalytera Therapeutics, Inc. CENTRAL INDEX KEY: 0001639643 IRS NUMBER: 471374952 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-349524 FILM NUMBER: 191110896 BUSINESS ADDRESS: STREET 1: 4040 CIVIC CENTER DRIVE, SUITE 200 CITY: SAN RAFAEL STATE: CA ZIP: 94903 BUSINESS PHONE: 888-861-2008 MAIL ADDRESS: STREET 1: 4040 CIVIC CENTER DRIVE, SUITE 200 CITY: SAN RAFAEL STATE: CA ZIP: 94903 D 1 primary_doc.xml X0708 D LIVE 0001639643 Kalytera Therapeutics, Inc. 4040 CIVIC CENTER DRIVE, SUITE 200 SAN RAFAEL CA CALIFORNIA 94903 888-861-2008 BRITISH COLUMBIA, CANADA None None Corporation true 2016 Robert Farrell 4040 CIVIC CENTER DRIVE, SUITE 200 SAN RAFAEL CA CALIFORNIA 94903 Executive Officer Director Ronald Erickson 4040 CIVIC CENTER DRIVE, SUITE 200 SAN RAFAEL CA CALIFORNIA 94903 Director Robin Hutchison 4040 CIVIC CENTER DRIVE, SUITE 200 SAN RAFAEL CA CALIFORNIA 94903 Director Jeff Paley 4040 CIVIC CENTER DRIVE, SUITE 200 SAN RAFAEL CA CALIFORNIA 94903 Director Victoria Rudman 4040 CIVIC CENTER DRIVE, SUITE 200 SAN RAFAEL CA CALIFORNIA 94903 Executive Officer Other Decline to Disclose 06c false 2019-09-13 false true true true false 760 Alere Financial Partners, a division of Cova Capital Partners LLC 109761 None None 6851 JERICHO TURNPIKE, SUITE 120A SYOSSET NY NEW YORK 11791 CA CALIFORNIA GA GEORGIA KY KENTUCKY MA MASSACHUSETTS NJ NEW JERSEY NY NEW YORK WA WASHINGTON false 2407562 760000 1647562 Estimated amounts are based on CAD$1.3153/USD$1.00 exchange rate on 2019-09-10, when the offering price was set. Total Offering Amount includes aggregate exercise price of USD$1,267,138 in respect of unexercised warrants issued as part of the offering. false 11 23120 true 0 The estimated amount is based on CAD$1.3153/USD$1.00 exchange rate PLUS 675,788 common share purchase warrants. 0 false Kalytera Therapeutics, Inc. /s/ Robert Farrell Robert Farrell President, CEO and Director 2019-09-24